IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 56
- 试验地点
- 8
- 主要终点
- The Proportion of Patients With CDK12 Loss of Function Metastatic CRPC That Respond to Treatment.
研究概览
简要总结
This study will attempt to determine the efficacy of checkpoint inhibitor immunotherapy with nivolumab and ipilimumab combination therapy followed by nivolumab monotherapy in patients with metastatic prostate cancer and other tumor solid tumor histologies harboring loss of CDK12 function as well as monotherapy nivolumab treatment in patient with metastatic prostate cancer harboring loss of CDK12 function.
详细描述
This study investigates the efficacy of checkpoint inhibitor immunotherapy in patients with metastatic cancer with CDK12 mutations. The study includes three cohorts: Cohort A consists of metastatic prostate cancer patients being treated with combination nivolumab and ipilimumab treatment followed by monotherapy nivolumab treatment. Cohort B consists of other solid tumor patients being treated with combination nivolumab and ipilimumab treatment followed by monotherapy nivolumab treatment. As of an amendment approved 03FEB2021 a third cohort was added, Cohort C, which consists of metastatic prostate cancer patients being treated with monotherapy nivolumab treatment.
As of an amendment approved 21JUN2020 the maximum duration of treatment, as well as the anticipated timing for some of the studies outcome measures, were updated from 52 weeks to 104 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be ≥18 years of age as of date of signing informed consent.
- •Be willing and able to provide written informed consent for the study.
- •ECOG Performance Status of 0, 1 or 2 (Eastern Cooperative Oncology Group scoring system used to quantify general well-being and activities of daily life; scores range from 0 to 5 where 0 represents perfect health and 5 represents death.
- •Subjects must have a histologic or cytologic diagnosis of metastatic adenocarcinoma of the prostate without small cell histology OR another type of metastatic carcinoma.
- •All subjects, regardless of cancer type, must have a documented CDK12 aberration in tumor tissue.
- •Subjects with prostate cancer must have documented prostate cancer progression within six months prior to screening with PSA progression defined as a minimum of three rising PSA levels ≥ 1; 1 week between each assessment with a baseline PSA value at screening of ≥ 2 ng/mL.
- •Subjects with prostate cancer must have ongoing androgen deprivation with total serum testosterone < 50 ng/dL (or ≤ 0.50 ng/mL or 1.73 nmol/L)). If the subject is currently being treated with LHRH agonists (subjects who have not undergone an orchiectomy), this therapy must have been initiated at least 4 weeks prior to registration. This treatment must be continued throughout the study.
- •Subjects with non-prostate histologies must have RECIST 1.1-measurable cancer on computed tomography (CT) or magnetic resonance imaging (MRI) scans.
- •Subjects must have recovered to baseline or ≤ grade 1 toxicities related to any prior treatments unless AE(s) are clinically non-significant and/or stable.
- •Patients must be ≥ 2 weeks from most recent systemic therapy or most recent radiation therapy.
- •Women of childbearing potential must have a negative serum or urine pregnancy test within 28 days prior to registration.
- •Female and male subjects of reproductive potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 5 months (for women) and 7 months (for men) after the last dose of study therapy.
- •Adequate organ and marrow function
排除标准
- •Prior treatment with anti-PD-1/PD-L1 and anti-CTLA-4 is NOT allowed. Prior intravesical BCG therapy is allowed.
- •Treatment with any investigational agent or on an interventional clinical trial within 28 days prior to registration.
- •Prior or concurrent malignancy except for: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, localized or locally advanced prostate cancer definitively treated without recurrence or with biochemical recurrence only, or any other cancer fully treated or from which the subject has been disease-free for at least 2 years.
- •Autoimmune diseases such as rheumatoid arthritis. Vitiligo, mild psoriasis (topical therapy only) or hypothyroidism are allowed.
- •Need for systemic corticosteroids >10mg prednisone daily or equivalent alternative steroid (except physiologic dose for adrenal replacement therapy) or other immunosuppressive agents (such as cyclosporine or methotrexate) Topical and inhaled corticosteroids are allowed if medically needed.
- •Any history of organ allografts
- •Any history of HIV, hepatitis B or hepatitis C infection
研究组 & 干预措施
Metastatic CRPC
Patients with metastatic castration resistant prostate cancer (mCRPC) will be enrolled in cohort A.
干预措施: Nivolumab (Drug)
Metastatic CRPC
Patients with metastatic castration resistant prostate cancer (mCRPC) will be enrolled in cohort A.
干预措施: Ipilimumab (Drug)
Solid Tumors (non-prostate)
Patients with all other metastatic subtypes will be enrolled in cohort B
干预措施: Nivolumab (Drug)
Solid Tumors (non-prostate)
Patients with all other metastatic subtypes will be enrolled in cohort B
干预措施: Ipilimumab (Drug)
Metastatic CRPC with Monotherapy
Patients with metastatic castration resistant prostate cancer (mCRPC) will be enrolled in cohort C once enrollment to cohort A has been completed.
干预措施: Nivolumab (Drug)
结局指标
主要结局
The Proportion of Patients With CDK12 Loss of Function Metastatic CRPC That Respond to Treatment.
时间窗: Up to 24 months post treatment
The primary objective is overall response rate (ORR) of patients with metastatic CRPC. Response will be defined as a 50% decline in PSA (prostate specific antigen) from baseline as determined by PCWG3 criteria.
次要结局
- The Proportion of Patients That Respond to Treatment in Cohort B.(Up to 104 weeks after start of therapy)
- Radiographic Progression Free Survival Time (rPFS)(Up to 104 weeks after start of therapy)
- Progression Free Survival Time (PFS)(Up to 24 months post treatment)
- Duration of Therapy (DOT)(Up to 104 weeks after start of therapy)
- Progression Rate at 6 Months(6 months)
- Overall Survival Time(Up to 24 months post treatment)
- PSA Progression Free Survival Time(Up to 24 months post treatment)
- Time to PSA Progression(Up to 24 months post treatment)